Literature DB >> 14662021

Expression of pericyte, mesangium and muscle markers in malignant rhabdoid tumor cell lines: differentiation-induction using 5-azacytidine.

Hirofumi Kato1, Shigeru Ohta, Shigeki Koshida, Tsutomu Narita, Takashi Taga, Yoshihiro Takeuchi, Kanji Sugita.   

Abstract

Malignant rhabdoid tumor (MRT) has been considered to have multiphenotypic diversity characteristics. Some MRTs exhibit a neural phenotype. However, it is still unclear whether MRT cells can display a skeletal muscle, smooth muscle or smooth muscle-like cell phenotype, like those of pericytes and mesangial cells. To determine if MRTs exhibit skeletal muscle cell or smooth muscle-like cell phenotypes, six MRT cell lines (TM87-16, STM91-01, TTC549, TTC642, YAM-RTK1 and TTC1240) were examined for markers of skeletal muscle (MyoD, myogenin, myf-5, myf-6, acetylcholine receptor-alpha, -beta and -gamma), smooth muscle (alpha-smooth muscle actin, SM-1 and SM22), and smooth muscle-like cells, such as pericytes (angiopoietin-1 and -2) and mesangial cells (megsin), using conventional RT-PCR, semi-quantitative PCR, western blotting and immunocytochemistry before and after differentiation-induction with 5-azacytidine. alpha-Smooth muscle actin and SM22 were detected in all six MRT cell lines, while MyoD and myf-5, crucial markers for skeletal myogenic determination, were not. The TM87-16 cell line expressed SM-1 and angiopoietin-1. TTC1240 also expressed angiopoietin-1. Interestingly, STM91-01 expressed megsin, a novel marker for mesangial cells, in addition to angiopoietin-1. Our results indicated that some MRTs exhibited smooth muscle and/or smooth muscle-like cell phenotypes and some renal MRTs might be of mesangial origin. Recently, smooth muscle and also smooth muscle-like cells have been considered to be of neuroectodermal origin. MRT can thus considered to belong to the category of primitive neuroectodermal tumors (PNETs) in the broad sense.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662021     DOI: 10.1111/j.1349-7006.2003.tb01401.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  5 in total

1.  Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice.

Authors:  Jessica DelBove; Yasumichi Kuwahara; E Lorena Mora-Blanco; Virginia Godfrey; William K Funkhouser; Christopher D M Fletcher; Terry Van Dyke; Charles W M Roberts; Bernard E Weissman
Journal:  Mol Carcinog       Date:  2009-12       Impact factor: 4.784

Review 2.  Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas.

Authors:  Sara Siddiqi; Joslyn Mills; Igor Matushansky
Journal:  Curr Stem Cell Res Ther       Date:  2010-03       Impact factor: 3.828

3.  Establishment and characterization of MRT cell lines from genetically engineered mouse models and the influence of genetic background on their development.

Authors:  Yasumichi Kuwahara; E Lorena Mora-Blanco; Fatima Banine; Arlin B Rogers; Christopher Fletcher; Larry S Sherman; Charles W M Roberts; Bernard E Weissman
Journal:  Int J Cancer       Date:  2012-12-27       Impact factor: 7.396

4.  Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.

Authors:  Haruka Shinohara; Rie Sawado; Makoto Nakagawa; Ayuna Hattori; Kazutsune Yamagata; Kimiharu Tauchi; Jumpei Ito; Yasumichi Kuwahara; Tsukasa Okuda; Chitose Ogawa; Issay Kitabayashi
Journal:  Mol Ther Oncolytics       Date:  2022-09-19       Impact factor: 6.311

5.  Augmentation of neovascularization [corrected] in hindlimb ischemia by combined transplantation of human embryonic stem cells-derived endothelial and mural cells.

Authors:  Kenichi Yamahara; Masakatsu Sone; Hiroshi Itoh; Jun K Yamashita; Takami Yurugi-Kobayashi; Koichiro Homma; Ting-Hsing Chao; Kazutoshi Miyashita; Kwijun Park; Naofumi Oyamada; Naoya Sawada; Daisuke Taura; Yasutomo Fukunaga; Naohisa Tamura; Kazuwa Nakao
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.